Durvalumab is an anti-PD-L1 antibody that was approved with a VENTANA PD-L1 (SP 263) assay and is indicated as monotherapy for the treatment of locally advanced, unresectable non-small-cell lung cancer (NSCLC) in patients who have PD-L1-positive NSCLC that has not progressed following platinum-based radio-chemotherapy. Here, CD274 is linked to non-small cell lung carcinoma.